A Phase 2 interventional study of Florbetaben (BAY94-9172) in Alzheimer Disease and Amyloid Beta-Protein, sponsored by Lantheus Biosciences Ltd.. Completed at 23 sites in 5 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Alzheimer Disease with a site in Germany — 26 open to participants now, 39 under way, 17 of them phase 3. Alzheimer Disease · Germany.
Among the 213 studies in Alzheimer Disease with a site in Germany, this one is the 83rd largest by enrollment of the 193 interventional ones that give a count, is one of 15 that started in 2008, is one of 57 in phase 2, and was the 35th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →26 of the 213 studies in Alzheimer Disease with a site in Germany are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany, United States, Australia and 2 more countries
Ages 50–90
Sanofi · Sites in Germany, United States, Australia and 4 more countries
Ages 55–85
Exciva GmbH · Sites in Germany, United States, Canada and 6 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 23 more countries
Ages 55–90
Technical University of Munich · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 74 · Phase 3 87 · Phase 4 5
First in 2002; this study’s year is marked. 15 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 422 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 356 across the 193 interventional studies, 170 across the 20 observational. Of the 162 that completed or were terminated, 79 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 213 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lantheus Biosciences Ltd., one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Biosciences Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Lantheus Holdings, Inc. has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
8 of the studies in Alzheimer Disease with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
| NCT06544616Janssen Pharmaceutica N.V., BelgiumA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | 2026-12-22 |
Add all 8 to your calendar (.ics) → With an account.
Among the 213 studies in Alzheimer Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations
Inclusion Criteria:
Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:
Inclusion criteria for HV only:
Inclusion criteria for patients with AD only:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Florbetaben (BAY94-9172)
Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth
Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final
Time frame: 90 - 110 min after investigational medical product (IMP) injection
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.
Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.
Time frame: 90 - 110 min after IMP injection
Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment
PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed
Time frame: 45 - 60 min and 110 - 130 min after IMP injection
Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)
The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient. Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.
Time frame: 45-60 min, 90-110 min, 110-130 min
Standard Uptake Value Ratios for Florbetaben Signal
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)
Time frame: 90-110 min post injection
There were two parts in this study, Part A and Part B. Part A was conducted in Australia, Germany, Switzerland and USA. Subjects were recruited from 17 centers. HVs were age matched to subjects with probable Alzheimer's (AD). Part B was conducted in Australia, Germany, Japan, Switzerland, and USA, subjects recruited from 22 centers.
| Milestone | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients |
|---|---|---|---|---|
| Started | 69 | 82 | 126 | 148 |
| Completed | 69 | 81 | 125 | 147 |
| Not completed | 0 | 1 | 1 | 1 |
Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final
| percentage of subjects | AD (Sensitivity) Group | HV (Specificity) Group |
|---|---|---|
| Majority Read Sens/ Spec (BAPL2 = abnormal) | 79.49 (70.47 to 88.51) | 91.18 (84.38 to 97.97) |
| Average Sens / Spec (BAPL2 = normal) | 74.79 (65.69 to 83.88) | 96.08 (91.85 to 100.30) |
Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.
| percentage of subjects | AD (Sensitivity) Group | HV (Specificity) Group |
|---|---|---|
| Sens / Spec (average 3 readers) | 67.24 (58.70 to 75.78) | 96.61 (93.34 to 99.88) |
| Sens / Spec (additional read, median 5 readers) | 78.5 (71.0 to 85.9) | 89.2 (83.6 to 94.7) |
PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed
| percentage of subjects | AD (Sensitivity) Group (Part A) | HV (Specificity) Group (Part A) | AD (Sensitivity) Group (Part B) | HV (Specificity) Group (Part B) |
|---|---|---|---|---|
| Sensitivity & Specificity (45-60 min) | 73.93 (64.88 to 82.98) | 94.61 (90.36 to 98.85) | 71.55 (63.34 to 79.76) | 94.07 (89.81 to 96.55) |
| Sensitivity & Specificity (110-130 min) | 70.56 (60.98 to 80.15) | 98.01 (95.65 to 100.37) | 73.04 (64.93 to 81.15) | 96.58 (93.29 to 99.87) |
The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient. Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.
| Kappa coefficient | Imaging Window 45-60 Min Part A | Imaging Window 90-110 Min Part A | Imaging Window 110-130 Min Part A | Imaging Window 45-60 Min Part B | Imaging Window 90-110 Min Part B | Imaging Window 110-130 Min Part B |
|---|---|---|---|---|---|---|
| Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score) | 0.56 | 0.60 | 0.67 | 0.78 | 0.86 | 0.86 |
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)
| ratio | Alzheimer's (AD) Group (Part A) | Healthy Volunteer (HV) Group (Part A) | Alzheimer's (AD) Group (Part B) | Healthy Volunteer (HV) Group (Part B) |
|---|---|---|---|---|
| Frontal cortex | 1.608 ± 0.3207 | 1.295 ± 0.1151 | 1.646 ± 0.2905 | 1.301 ± 0.1961 |
| Lateral temporal cortex | 1.571 ± 0.2881 | 1.259 ± 0.1058 | 1.619 ± 0.2787 | 1.292 ± 0.1620 |
| Parietal cortex | 1.528 ± 0.2896 | 1.234 ± 0.1161 | 1.602 ± 0.2705 | 1.267 ± 0.1709 |
| Anterior cingulate | 1.723 ± 0.3522 | 1.397 ± 0.1425 | 1.786 ± 0.3145 | 1.434 ± 0.2387 |
| Posterior cingulate cortex | 1.795 ± 0.3149 | 1.422 ± 0.1565 | 1.852 ± 0.3187 | 1.493 ± 0.2351 |
| Occipital cortex | 1.495 ± 0.2203 | 1.309 ± 0.0864 | 1.560 ± 0.2460 | 1.341 ± 0.1281 |
| Composite SUVR | 1.620 ± 0.29 | 1.320 ± 0.11 | 1.678 ± 0.2699 | 1.355 ± 0.1784 |
Collected over A maximum of 64 days. Up to 56 days during the screening process and 8 days from baseline to second follow-up visit.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Healthy Volunteers | — | 1/69 (1.4%) | 10/69 (14.5%) |
| Part A Alzheimer Patients | — | 1/81 (1.2%) | 3/81 (3.7%) |
| Part B Healthy Volunteers | — | 2/125 (1.6%) | 17/125 (13.6%) |
| Part B Alzheimer Patients | — | 0/147 (0%) | 23/147 (15.6%) |
| Event | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients |
|---|---|---|---|---|
| SyncopeNervous system disorders | 1/69 | 0/81 | 0/125 | 0/147 |
| ArrhythmiaCardiac disorders | 0/69 | 1/81 | 1/125 | 0/147 |
| Chest painGeneral disorders and administration site conditions | 0/69 | 1/81 | 0/125 | 0/147 |
| Clear cell endometrial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/69 | 0/81 | 1/125 | 0/147 |
| Event | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/69 | 0/81 | 2/125 | 2/147 |
| HaematomaVascular disorders | 1/69 | 1/81 | 7/125 | 4/147 |
| Injection site haematomaGeneral disorders and administration site conditions | 0/69 | 0/81 | 2/125 | 8/147 |
| Application site erythemaGeneral disorders and administration site conditions | 3/69 | 1/81 | 0/125 | 0/147 |
| Injection site erythemaGeneral disorders and administration site conditions | 1/69 | 0/81 | 1/125 | 6/147 |
| Injection site irritationGeneral disorders and administration site conditions | 0/69 | 0/81 | 4/125 | 1/147 |
| ErythemaSkin and subcutaneous tissue disorders | 2/69 | 1/81 | 0/125 | 0/147 |
| Injection site painGeneral disorders and administration site conditions | 0/69 | 0/81 | 2/125 | 3/147 |
1. dropout in Part A occurred due to pre-treatment AEs. 2. dropouts in Part B occurred due to withdrawal of consent.
| Age, Categorical(Participants) | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 19 | 21 | 15 | 78 |
| >=65 years | 46 | 62 | 104 | 132 | 344 |
| Age, Continuous(years) | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients | Total |
|---|---|---|---|---|---|
| Mean | 68.2 ± 6.86 | 70.7 ± 7.82 | 70.7 ± 6.30 | 73.9 ± 7.30 | 71.4 ± 7.36 |
| Sex: Female, Male(Participants) | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients | Total |
|---|---|---|---|---|---|
| Female | 39 | 36 | 52 | 73 | 200 |
| Male | 30 | 45 | 73 | 74 | 222 |
| Region of Enrollment(participants) | Part A Healthy Volunteers | Part A Alzheimer Patients | Part B Healthy Volunteers | Part B Alzheimer Patients | Total |
|---|---|---|---|---|---|
| United States | 8 | 3 | 22 | 31 | 64 |
| Australia | 9 | 6 | 11 | 5 | 31 |
| Germany | 49 | 71 | 63 | 72 | 255 |
| Switzerland | 3 | 1 | 0 | 11 | 15 |
| Japan | 0 | 0 | 29 | 28 | 57 |
The record gives a start of Aug 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 3 years 8 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Florbetaben f-18